A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease
Translational Neurodegeneration, 2023
Faridar A., Eid A., Thome A., Zhao W., Beers D., Pascual M., Nakawah M., Roman G., Davis C., Grundman M., Masdeu J., Appel S.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Neurology Immunotherapy | Pathophysiology | Plasma |  Olink Target 48 |
Abstract
Trial registration
ClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, https://classic.clinicaltrials.gov/ct2/show/NCT05821153